BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 34599001)

  • 1. Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry.
    Thaler FS; Zimmermann L; Kammermeier S; Strippel C; Ringelstein M; Kraft A; Sühs KW; Wickel J; Geis C; Markewitz R; Urbanek C; Sommer C; Doppler K; Penner L; Lewerenz J; Rößling R; Finke C; Prüss H; Melzer N; Wandinger KP; Leypoldt F; Kümpfel T;
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34599001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF Findings in Acute NMDAR and LGI1 Antibody-Associated Autoimmune Encephalitis.
    Dürr M; Nissen G; Sühs KW; Schwenkenbecher P; Geis C; Ringelstein M; Hartung HP; Friese MA; Kaufmann M; Malter MP; Madlener M; Thaler FS; Kümpfel T; Senel M; Häusler MG; Schneider H; Bergh FT; Kellinghaus C; Zettl UK; Wandinger KP; Melzer N; Gross CC; Lange P; Dreyhaupt J; Tumani H; Leypoldt F; Lewerenz J;
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34697224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term seizure outcomes in patients with autoimmune encephalitis: A prospective observational registry study update.
    Liu X; Guo K; Lin J; Gong X; Li A; Zhou D; Hong Z
    Epilepsia; 2022 Jul; 63(7):1812-1821. PubMed ID: 35357695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF-Neurofilament Light Chain Levels in NMDAR and LGI1 Encephalitis: A National Cohort Study.
    Nissen MS; Ryding M; Nilsson AC; Madsen JS; Olsen DA; Halekoh U; Lydolph M; Illes Z; Blaabjerg M
    Front Immunol; 2021; 12():719432. PubMed ID: 34975832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seizures and risk of epilepsy in anti-NMDAR, anti-LGI1, and anti-GABA
    Shen CH; Fang GL; Yang F; Cai MT; Zheng Y; Fang W; Guo Y; Zhang YX; Ding MP
    Ann Clin Transl Neurol; 2020 Aug; 7(8):1392-1399. PubMed ID: 32710704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum and CSF cytokine levels mirror different neuroimmunological mechanisms in patients with LGI1 and Caspr2 encephalitis.
    Körtvelyessy P; Goihl A; Guttek K; Schraven B; Prüss H; Reinhold D
    Cytokine; 2020 Nov; 135():155226. PubMed ID: 32799011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of 28 cases of anti
    Feng J; Li J; Xie Y; Lü Y; Bi F; Zhou J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):386-396. PubMed ID: 37164922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Seizure Recurrence Due to Autoimmune Encephalitis With NMDAR, LGI1, CASPR2, and GABA
    Rada A; Hagemann A; Aaberg Poulsen C; Baumgartner T; Berki T; Blaabjerg M; Brenner J; Britton JW; Christiana A; Ciano-Petersen NL; Crijnen Y; Elišák M; Farina A; Friedman AR; Hayden Z; Hébert J; Holtkamp M; Hong Z; Honnorat J; Ilyas-Feldmann M; Irani SR; Kovac S; Marusic P; Muñiz-Castrillo S; Ramanathan S; Smith KM; Steriade C; Strippel C; Surges R; Titulaer MJ; Uy CE; de Vries JM; Bien CG; Specht U
    Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200225. PubMed ID: 38838283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seizure Semiology in Antibody-Associated Autoimmune Encephalitis.
    Kaaden T; Madlener M; Angstwurm K; Bien CG; Bogarin Y; Doppler K; Finke A; Gerner ST; Reimann G; Häusler M; Handreka R; Hellwig K; Kaufmann M; Kellinghaus C; Koertvelyessy P; Kraft A; Lewerenz J; Menge T; Paliantonis A; von Podewils F; Prüss H; Rauer S; Ringelstein M; Rostásy K; Schirotzek I; Schwabe J; Sokolowski P; Suesse M; Sühs KW; Surges R; Tauber SC; Thaler F; Bergh FT; Urbanek C; Wandinger KP; Wildemann B; Mues S; Zettl U; Leypoldt F; Melzer N; Geis C; Malter M; Kunze A;
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36266054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Recovery in Autoimmune Encephalitis: A Prospective Observational Study.
    Seifert-Held T; Eberhard K; Lechner C; Macher S; Hegen H; Moser T; Jacob GB; Puttinger G; Topakian R; Guger M; Kacar E; Zoche L; De Simoni D; Seiser A; Oberndorfer S; Baumgartner C; Struhal W; Zimprich F; Sellner J; Deisenhammer F; Enzinger C; Reindl M; Rauschka H; Berger T; Höftberger R
    Front Immunol; 2021; 12():641106. PubMed ID: 34093529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody induced seizure susceptibility and impaired cognitive performance in a passive transfer rat model of autoimmune encephalitis.
    Pişkin ŞA; Korkmaz HY; Ulusoy CA; Şanlı E; Küçükali CI; Onat F; Tüzün E; Çarçak N
    Front Immunol; 2023; 14():1268986. PubMed ID: 38035091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-positive autoimmune encephalitis and paraneoplastic neurological syndrome: A Swedish case series.
    Kosek S; Burman J; Punga AR
    Brain Behav; 2024 May; 14(5):e3534. PubMed ID: 38702897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival Analysis of Immunotherapy Effects on Relapse Rate in Pediatric and Adult Autoimmune Encephalitis.
    Yang JH; Liu EN; Nguyen L; Dunn-Pirio A; Graves JS
    Neurology; 2023 Nov; 101(22):e2300-e2313. PubMed ID: 37827848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics, long-term functional outcomes and relapse of anti-LGI1/Caspr2 encephalitis: a prospective cohort study in Western China.
    Guo K; Liu X; Lin J; Gong X; Li A; Liu Y; Zhou D; Hong Z
    Ther Adv Neurol Disord; 2022; 15():17562864211073203. PubMed ID: 35069805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomes expressing neuronal autoantigens induced immune response in antibody-positive autoimmune encephalitis.
    Gu J; Jin T; Li Z; Chen H; Xia H; Xu X; Gui Y
    Mol Immunol; 2021 Mar; 131():164-170. PubMed ID: 33446390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of serum anti-neuronal autoantibodies in patients admitted to acute psychiatric care.
    Schou M; Sæther SG; Borowski K; Teegen B; Kondziella D; Stoecker W; Vaaler A; Reitan SK
    Psychol Med; 2016 Dec; 46(16):3303-3313. PubMed ID: 27609625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical issues in measuring autoantibodies to neuronal cell-surface antigens in autoimmune neurological disorders: 190 cases.
    Kaneko J; Kanazawa N; Tominaga N; Kaneko A; Suga H; Usui R; Ishima D; Kitamura E; Akutsu T; Yoshida K; Nishiyama K; Iizuka T
    J Neurol Sci; 2018 Jul; 390():26-32. PubMed ID: 29801900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro neuronal network activity as a new functional diagnostic system to detect effects of Cerebrospinal fluid from autoimmune encephalitis patients.
    Koch H; Niturad CE; Theiss S; Bien CG; Elger C; Wandinger KP; Vincent A; Malter M; Körtvelyessy P; Lerche H; Dihné M
    Sci Rep; 2019 Apr; 9(1):5591. PubMed ID: 30944364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis.
    Wickel J; Chung HY; Platzer S; Lehmann T; Prüss H; Leypoldt F; Günther A; Scherag A; Geis C;
    Trials; 2020 Jul; 21(1):625. PubMed ID: 32641101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies).
    Bastiaansen AEM; van Sonderen A; Titulaer MJ
    Curr Opin Neurol; 2017 Jun; 30(3):302-309. PubMed ID: 28248701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.